Emergent Biosolutions Inc. EBS

Healthcare — Drug Manufacturers Specialty & Generic

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
Revenue	488.80	560.90	782.40	1,106.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Revenue Growth	(0.11%)	14.75%	39.49%	41.36%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Cost of Revenue	126.30	187.70	322.30	433.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Gross Profit	362.50	373.20	460.10	672.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
R&D Expenses	106.90	97.40	142.80	226.20	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
SG&A Expenses	143.10	142.90	202.50	273.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating Income	105.50	124.30	89.80	114.10	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Expense (Operating)	8.00	7.00	10.00	39.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	—	—
Non-operating Income/Expense	(6.30)	(5.70)	(8.30)	(36.70)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Non-operating Interest Expenses	7.60	6.60	9.90	38.40	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBT	99.20	118.60	81.50	77.40	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Income Tax Provision	36.70	36.00	18.80	22.90	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Income after Tax	62.50	82.60	62.70	54.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Dividends (Preferred)	—	—	—	—	—	‡‡‡	—	—	‡‡‡	‡‡‡
Net Income Common	51.80	82.60	62.70	54.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Basic)	1.29	1.98	1.25	1.06	‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡
EPS (Diluted)	1.13	1.71	1.22	1.04	‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡
Shares (Basic, Weighted)	40.20	41.80	50.10	51.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Shares (Diluted, Weighted)	49.30	50.30	51.40	52.40	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Gross Margin	74.16%	66.54%	58.81%	60.80%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBIT Margin	21.58%	22.16%	11.48%	10.32%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBT margin	20.29%	21.14%	10.42%	7.00%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Profit Margin	10.60%	14.73%	8.01%	4.93%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow Margin	(4.42%)	27.33%	(3.54%)	9.14%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBITDA	143.70	168.60	152.90	227.80	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBIT	105.50	124.30	89.80	114.10	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Income from Continuous Operations	62.50	82.60	62.70	54.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Income from Discontinued Operations	(10.70)	—	—	—	—	—	—	—	—	—
Consolidated Net Income/Loss	51.80	82.60	62.70	54.50	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Basic, from Continuous Ops)	1.56	1.98	1.25	1.06	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Basic, from Discontinued Ops)	(0.27)	—	—	—	—	—	—	—	—	—
EPS (Basic, Consolidated)	1.29	1.98	1.25	1.06	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Diluted, from Cont. Ops)	1.35	1.64	1.22	1.04	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Diluted, from Disc. Ops)	0.00	—	—	—	—	—	—	—	—	—
Shares (Diluted, Average)	49.34	50.33	51.40	52.40	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EPS (Diluted, Consolidated)	1.05	1.64	1.22	1.04	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EBITDA Margin	29.40%	30.06%	19.54%	20.60%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating Cash Flow Margin	11.17%	37.10%	5.34%	17.00%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now